1 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Journal of the American Academy of Dermatology
Volume 71, n° 1
pages 1.e1-1.e8 (juillet 2014)
Doi : 10.1016/j.jaad.2014.01.875
accepted : 25 January 2014
Continuing Medical Education

Proactive infectious disease approach to dermatologic patients who are taking tumor necrosis factor–alfa antagonists : Part I. Risks associated with tumor necrosis factor–alfa antagonists

Lisa M. Chirch, MD a, Philip R. Cataline, MD a, Kevin D. Dieckhaus, MD a, Jane M. Grant-Kels, MD b,
a Department of Medicine, Division of Infectious Diseases, University of Connecticut Health Center, Farmington, Connecticut 
b Department of Dermatology, University of Connecticut Health Center, Farmington, Connecticut 

Correspondence to: Jane M. Grant-Kels, MD, University of Connecticut Health Center, Department of Dermatology, 21 South Rd, Farmington, CT 06032.

Tumor necrosis factor–alfa levels are linked to disease severity in patients with inflammatory conditions, such as psoriasis. Inhibitors of this cytokine are commonly used with significant success in the treatment of such inflammatory disorders. Their use, however, can be plagued by infectious complications. An awareness of potential infections associated with these therapies is critical in order to maximize preventive efforts both before and during therapy. This review provides a guide for dermatologists caring for patients in need of this type of biologic therapy to preemptively address the infectious risks. Part I of this continuing medical education article reviews background information on the various infectious risks associated with tumor necrosis factor inhibitor therapy and appropriate historical data to obtain in the context of pretherapy evaluations.

The full text of this article is available in PDF format.

Key words : biologic therapy, endemic mycoses, opportunistic infection, psoriasis, tuberculosis, tumor necrosis factor

 Funding sources: None.
 Conflicts of interest: None declared.

© 2014  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline